Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0382)
| Name |
Astragalus polysaccharide
|
||||
|---|---|---|---|---|---|
| Drug Type |
Small molecule
|
||||
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
| In total 1 item(s) under this Target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Ulcerative colitis | ICD-11: DD71 | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vitro Model | Caco-2 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | |
| In Vivo Model |
Six-eight-week-old male C57BL/6 mice weighing 19.74 ± 0.77 g were purchased from Shanghai Laboratory. To investigate the therapeutic effect of APS on DSS-induced colitis, mice were randomly divided into the following 5 groups (n = 5 each): control, DSS, DSS + APS (100 mg/kg), DSS + APS (200 mg/kg), and DSS + APS (300 mg/kg). The mice in the DSS + APS (100 mg/kg), DSS + APS (200 mg/kg), and DSS + APS (300 mg/kg) groups were intraperitoneally injected with 100, 200, and 300 mg/kg APS once a day, respectively from day 3 to day 10.
Click to Show/Hide
|
||||
| Response regulation | The therapeutic effects of Astragalus polysaccharide on DSS-induced Ulcerative colitis by blocking ferroptosis in IECs. Furthermore, our results revealed that APS-mediated inhibition of ferroptosis was associated with the NRF2/HO-1 pathway. | ||||